Donald Healey
Directeur Technique/Scientifique/R&D chez ADICET BIO, INC.
Fortune : 63 764 $ au 30/04/2024
Profil
Donald Healey is currently the Chief Technology Officer at Adicet Bio, Inc. He was previously the Senior Vice President-Operations at KBI Biopharma, Inc. from 2017 to 2020 and the Chief Scientific Officer at Opexa Therapeutics, Inc. from 2013 to 2017.
He also worked as the Director-Immunology at Argos Therapeutics, Inc. and as a Council Member at the British Society for Immunology.
He holds a doctorate degree from the University of London and an undergraduate degree from the University of Bristol.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ADICET BIO INC
0,04% | 09/04/2024 | 35 229 ( 0,04% ) | 63 764 $ | 30/04/2024 |
Postes actifs de Donald Healey
| Sociétés | Poste | Début |
|---|---|---|
| ADICET BIO, INC. | Directeur Technique/Scientifique/R&D | 26/10/2020 |
Anciens postes connus de Donald Healey
| Sociétés | Poste | Fin |
|---|---|---|
KBI Biopharma, Inc.
 KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Directeur des opérations | 01/10/2020 |
Opexa Therapeutics, Inc.
 Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Directeur Technique/Scientifique/R&D | 01/02/2017 |
British Society for Immunology
 British Society for Immunology Miscellaneous Commercial ServicesCommercial Services The British Society for Immunology provides membership organization services. The non-profit company is based in London, UK. | Corporate Officer/Principal | 01/01/1998 |
| ARGOS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Donald Healey
| University of London | Doctorate Degree |
| University of Bristol | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ADICET BIO, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
KBI Biopharma, Inc.
KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Commercial Services |
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Health Technology |
British Society for Immunology
British Society for Immunology Miscellaneous Commercial ServicesCommercial Services The British Society for Immunology provides membership organization services. The non-profit company is based in London, UK. | Commercial Services |